Related Experiment Video
Updated: Jun 24, 2026
07:43
Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
Published on: January 17, 2018
19.2K
Towards precision medicine for clinically non-functioning pituitary tumours.
Nèle F Lenders1,2,3, Warrick J Inder4,5, Ann I McCormack1,2,3
1Department of Endocrinology, St Vincent's Hospital, Sydney, New South Wales, Australia.
Clinical Endocrinology
|March 28, 2021
Summary
Clinically non-functioning pituitary tumours (NFPT) have diverse outcomes. Research is identifying clinical, pathological, and genetic factors to predict NFPT recurrence and guide personalized treatment.
Area of Science:
- Endocrinology
- Oncology
- Pathology
Background:
- Clinically non-functioning pituitary tumours (NFPT) represent a heterogeneous group of neoplasms with variable clinical trajectories.
- Understanding predictive factors is crucial for managing NFPT effectively in both clinical practice and research.
Purpose of the Study:
- To review and summarize existing data on predictive factors for non-functioning pituitary tumours.
- To consolidate information on clinical, radiological, pathological, and genetic markers associated with NFPT outcomes.
Main Methods:
- A comprehensive literature review was performed.
- Included studies were published in peer-reviewed journals.
- Focused on identifying predictive factors in non-functioning pituitary tumours.
Main Results:
- Clinical and radiological factors like tumour size and growth rates correlate with NFPT recurrence and aggressiveness.
- Immunohistochemistry aids in identifying higher-risk NFPT subtypes in clinical settings.
- Various pathological and genetic biomarkers show potential for prognostication in research.
Conclusions:
- Non-functioning pituitary tumours exhibit significant heterogeneity in presentation, pathogenesis, and outcomes.
- Advances in understanding tumour biology will enhance prognostication and enable precision medicine for NFPT.
Keywords:
aggressionbiomarkershumanimmunohistochemistrypituitary neoplasmsprecision medicineprognosistranscription factorsMore Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...